Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study.

Yukawa N, Fujii T, Kondo-Ishikawa S, Yoshifuji H, Kawabata D, Nojima T, Ohmura K, Usui T, Mimori T.

Arthritis Res Ther. 2011;13(6):R213. doi: 10.1186/ar3546. Epub 2011 Dec 22.

2.

Determination of ANA specificity using multiplexed fluorescent microsphere immunoassay in patients with ANA positivity at high titres after infliximab treatment: preliminary results.

Caramaschi P, Ruzzenente O, Pieropan S, Volpe A, Carletto A, Bambara LM, Biasi D.

Rheumatol Int. 2007 May;27(7):649-54. Epub 2006 Nov 29.

PMID:
17136355
3.

Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.

De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F.

Arthritis Rheum. 2003 Apr;48(4):1015-23.

4.

Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.

Bruns A, Nicaise-Roland P, Hayem G, Palazzo E, Dieudé P, Grootenboer-Mignot S, Chollet-Martin S, Meyer O.

Joint Bone Spine. 2009 May;76(3):248-53. doi: 10.1016/j.jbspin.2008.09.010. Epub 2009 Feb 8.

PMID:
19208451
5.

Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.

Caramaschi P, Biasi D, Colombatti M, Pieropan S, Martinelli N, Carletto A, Volpe A, Pacor LM, Bambara LM.

Rheumatol Int. 2006 Jan;26(3):209-14. Epub 2004 Dec 31.

PMID:
15627197
6.

[Antinuclear, anti-dsDNA and anti-ENA antibodies in patients affected with rheumatoid arthritis or ankylosing spondylitis during treatment with infliximab].

Hoxha A, Ruffatti A, Grypiotis P, Podswiadek M, Botsios C, Fiocco U, Punzi L, Todesco S.

Reumatismo. 2006 Apr-Jun;58(2):121-6. Italian.

7.

Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.

Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ.

J Rheumatol. 2006 Jan;33(1):24-30.

PMID:
16395746
8.

Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis.

Benucci M, Saviola G, Baiardi P, Cammelli E, Manfredi M.

Clin Rheumatol. 2008 Jan;27(1):91-5. Epub 2007 Oct 10.

PMID:
17929076
10.
11.

Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.

Atzeni F, Sarzi-Puttini P, Dell' Acqua D, de Portu S, Cecchini G, Cruini C, Carrabba M, Meroni PL.

Arthritis Res Ther. 2006;8(1):R3.

12.

Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab.

Elkayam O, Burke M, Vardinon N, Zakut V, Yitzhak RB, Paran D, Levartovsky D, Litinsky I, Caspi D.

Autoimmunity. 2005 Mar;38(2):155-60.

PMID:
16040336
13.

Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment.

Caramaschi P, Biasi D, Tonolli E, Pieropan S, Martinelli N, Carletto A, Volpe A, Bambara LM.

Rheumatol Int. 2005 Nov;26(1):58-62. Epub 2005 Feb 23.

PMID:
15726373
14.

Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients.

Bacquet-Deschryver H, Jouen F, Quillard M, Ménard JF, Goëb V, Lequerré T, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.

J Clin Immunol. 2008 Sep;28(5):445-55. doi: 10.1007/s10875-008-9214-3. Epub 2008 Jun 28.

PMID:
18587633
15.

Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximab.

Iwata D, Namba K, Mizuuchi K, Kitaichi N, Kase S, Takemoto Y, Ohno S, Ishida S.

Graefes Arch Clin Exp Ophthalmol. 2012 Jul;250(7):1081-7. doi: 10.1007/s00417-011-1908-1. Epub 2012 Jan 11.

PMID:
22234352
16.

[TNF-alpha inhibition in anti-Ro/SSA positive patients with rheumatoid arthritis: clinical and immunologic effects].

Cavazzana I, Bobbio-Pallavicini F, Bazzani C, Bravi E, Zingarelli S, Ceribelli A, Caporali R, Cattaneo R, Franceschini F, Montecucco C.

Reumatismo. 2006 Oct-Dec;58(4):275-82. Italian.

17.
18.

Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.

Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S.

Ann Rheum Dis. 2005 Mar;64(3):403-7. Epub 2004 Aug 5.

19.

Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis.

Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, Ruiz Del Agua A, Martínez A, Aarden L, Martín-Mola E, Balsa A.

Rheumatology (Oxford). 2011 Aug;50(8):1445-52. doi: 10.1093/rheumatology/ker124. Epub 2011 Mar 22.

PMID:
21427177
20.

Positivity for antinuclear antibody in patients with advanced rheumatoid arthritis.

Nishimura S, Nishiya K, Hisakawa N, Chikazawa H, Ookubo S, Nakatani K, Hashimoto K.

Acta Med Okayama. 1996 Oct;50(5):261-5.

PMID:
8914679

Supplemental Content

Support Center